Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.

Szczegóły
Abstrakt

Tytuł:: Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
Autorzy:: Mohamed ASR; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt.
Cardenas CE; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA.
Garden AS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Awan MJ; Department of Radiation Oncology, Case Western Reserve University, Cleveland, USA.
Rock CD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Westergaard SA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Brandon Gunn G; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Belal AM; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt.
El-Gowily AG; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt.
Lai SY; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
Rosenthal DI; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Fuller CD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: .
Aristophanous M; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: .
Źródło:: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2017 Aug; Vol. 124 (2), pp. 248-255. Date of Electronic Publication: 2017 Jul 31.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Limerick : Elsevier Scientific Publishers
Original Publication: Amsterdam : Elsevier Science Publishers, c1983-
MeSH Terms:: Fluorodeoxyglucose F18*
Radiopharmaceuticals*
Head and Neck Neoplasms/*diagnostic imaging
Head and Neck Neoplasms/*radiotherapy
Positron Emission Tomography Computed Tomography/*methods
Radiotherapy Planning, Computer-Assisted/*methods
Adult ; Aged ; Aged, 80 and over ; Dose-Response Relationship, Radiation ; Female ; Head and Neck Neoplasms/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/radiotherapy ; Positron-Emission Tomography/methods ; Tomography, X-Ray Computed/methods ; Treatment Failure ; Tumor Burden
References:: Cancer Lett. 2014 Dec 28;355(2):169-75. (PMID: 25218590)
J Nucl Med. 2009 Jul;50(7):1020-7. (PMID: 19525447)
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1045-55. (PMID: 20643512)
Radiother Oncol. 2009 Jun;91(3):386-92. (PMID: 19329207)
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):670-7. (PMID: 17197123)
Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1117-26. (PMID: 10725621)
Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1544-9. (PMID: 18509637)
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):126-35. (PMID: 17448871)
Med Phys. 2011 May;38(5):2629-38. (PMID: 21776800)
J Nucl Med. 2009 May;50 Suppl 1:11S-20S. (PMID: 19380405)
Radiat Oncol. 2016 Jul 26;11(1):95. (PMID: 27460585)
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):377-85. (PMID: 18164838)
Semin Radiat Oncol. 2011 Apr;21(2):111-8. (PMID: 21356479)
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):28-42. (PMID: 15093896)
Med Phys. 2007 Nov;34(11):4223-35. (PMID: 18072487)
Radiother Oncol. 2008 Oct;89(1):13-8. (PMID: 18555547)
Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21. (PMID: 12527043)
BMC Cancer. 2013 Feb 22;13:84. (PMID: 23433435)
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):136-41. (PMID: 22541959)
Radiother Oncol. 2013 Feb;106(2):250-4. (PMID: 23395065)
Radiother Oncol. 2011 Dec;101(3):351-5. (PMID: 21742392)
Radiother Oncol. 2013 Jun;107(3):310-6. (PMID: 23647760)
Radiother Oncol. 2014 Jun;111(3):360-5. (PMID: 24993331)
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9226-33. (PMID: 10922074)
Radiology. 2015 Mar;274(3):752-63. (PMID: 25380454)
Crit Rev Oncol Hematol. 2016 Dec;108:40-51. (PMID: 27931839)
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):532-540. (PMID: 28258898)
Strahlenther Onkol. 2012 Aug;188(8):671-6. (PMID: 22580623)
Acta Oncol. 2013 Nov;52(8):1723-9. (PMID: 23317145)
Grant Information:: P30 CA016672 United States CA NCI NIH HHS; L30 CA136381 United States CA NCI NIH HHS; P50 CA097007 United States CA NCI NIH HHS; R01 DE025248 United States DE NIDCR NIH HHS; R01 CA214825 United States CA NCI NIH HHS; K12 CA088084 United States CA NCI NIH HHS; R56 DE025248 United States DE NIDCR NIH HHS; R01 CA218148 United States CA NCI NIH HHS
Contributed Indexing:: Keywords: Biological target volume; Dose escalation; FDG-PET; Head and neck cancer; Patterns of failure
Substance Nomenclature:: 0 (Radiopharmaceuticals)
0Z5B2CJX4D (Fluorodeoxyglucose F18)
Entry Date(s):: Date Created: 20170805 Date Completed: 20171229 Latest Revision: 20200306
Update Code:: 20240105
PubMed Central ID:: PMC5600500
DOI:: 10.1016/j.radonc.2017.07.017
PMID:: 28774596
: Czasopismo naukowe

Full Text Finder

Background: To identify the radio-resistant subvolumes in pretreatment FDG-PET by mapping the spatial location of the origin of tumor recurrence after IMRT for head-and-neck squamous cell cancer to the pretreatment FDG-PET/CT.
Methods: Patients with local/regional recurrence after IMRT with available FDG-PET/CT and post-failure CT were included. For each patient, both pre-therapy PET/CT and recurrence CT were co-registered with the planning CT (pCT). A 4-mm radius was added to the centroid of mapped recurrence growth target volumes (rGTV's) to create recurrence nidus-volumes (NVs). The overlap between boost-tumor-volumes (BTV) representing different SUV thresholds/margins combinations and NVs was measured.
Results: Forty-seven patients were eligible. Forty-two (89.4%) had type A central high dose failure. Twenty-six (48%) of type A rGTVs were at the primary site and 28 (52%) were at the nodal site. The mean dose of type A rGTVs was 71Gy. BTV consisting of 50% of the maximum SUV plus 10mm margin was the best subvolume for dose boosting due to high coverage of primary site NVs (92.3%), low average relative volume to CTV1 (41%), and least average percent voxels outside CTV1 (19%).
Conclusions: The majority of loco-regional recurrences originate in the regions of central-high-dose. When correlated with pretreatment FDG-PET, the majority of recurrences originated in an area that would be covered by additional 10mm margin on the volume of 50% of the maximum FDG uptake.
(Copyright © 2017 Elsevier B.V. All rights reserved.)

Informacja